TEST:

Prosigna™ Breast Cancer Prognostic Gene Signature Assay

P=N/A, N=200, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

P=N/A, N=1000, Enrolling by invitation, Casa Sollievo della Sofferenza IRCCS

Additionally, a 33-gene signature that predicted neoadjuvant Ki67 response to ANA/PAL was prognostic in a metastatic validation cohort. These findings underscore dysregulated oncogenic pathways as potential resistance mechanisms and biomarkers of response to CDK4/6i.

A larger study population in a prospective setting and more detailed outcome data would be necessary to understand the clinical relevance of the observed discrepancies. Only one evidence-based guideline-recommended prognostic test should be used in a single patient for CTX decision-making.

P=N/A, N=115, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting | N=241 --> 115 | Trial completion date: Oct 2027 --> Nov 2028 | Trial primary completion date: Apr 2026 --> Nov 2028

These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined non-luminal subtypes of HR+/HER2- mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post-endocrine treatment decisions.

Although not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.

Using the HIPPO interpretability method, we found that tumor regions were necessary and sufficient for high-risk predictions, and we identified candidate tissue biomarkers of recurrence. These results highlight the promise of interpretable, histology-based risk models in precision oncology.

RNA-based breast cancer subtyping suggests TP53 refines breast cancer etiologic heterogeneity in a sub-Saharan African population. The high prevalence of aggressive, mostly TP53-mutant tumors in this population underscores the need for further studies to clarify etiologic heterogeneity.

The results from the single-cell and deconvolution analyses confirmed subtype-specific immune microenvironments, which also allowed us to observe increased levels of natural killer (NK) and CD8+ T cells in Her2-enriched and Basal-like subtypes. In conclusion, our findings demonstrate significant differences in the immune tumor microenvironment between the established breast cancer molecular subtypes.

P2, N=671, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2025 --> May 2026

P2, N=5, Terminated, Fundacio Clinic Barcelona | N=17 --> 5 | Recruiting --> Terminated; The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible